Update on PEG-Interferon alpha -2b as Adjuvant Therapy in Melanoma
Based on the results of European Organization for Research and Treatment of Cancer (EORTC) 18991 trial, the US Food and Drug Administration (FDA) approved PEG-interferon alpha -2b (PEG-IFN)(Sylatron) as adjuvant therapy for high-risk melanoma. The EORTC 18991 trial was an open-label study of resecta...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2012-09, Vol.32 (9), p.3901-3909 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3909 |
|---|---|
| container_issue | 9 |
| container_start_page | 3901 |
| container_title | Anticancer research |
| container_volume | 32 |
| creator | Di Trolio, R Simeone, E Di Lorenzo, G Grimaldi, A M Romano, A Ayala, F Caraco, C Mozzillo, N Ascierto, P A |
| description | Based on the results of European Organization for Research and Treatment of Cancer (EORTC) 18991 trial, the US Food and Drug Administration (FDA) approved PEG-interferon alpha -2b (PEG-IFN)(Sylatron) as adjuvant therapy for high-risk melanoma. The EORTC 18991 trial was an open-label study of resectable stage III melanoma with 1,256 patients who were randomized to observation-alone or to treatment with PEG-IFN for up to 5 years. The median recurrence-free survival of the treatment groups was significantly longer, while overall survival, a secondary endpoint, was not significantly different between the two groups. This review, after a short summary of interferon alpha -2b trials, critically analyzes the EORTC18991 trial, as well as the subgroup results and future perspectives for this stage of disease. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1221145319</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1221143278</sourcerecordid><originalsourceid>FETCH-LOGICAL-p151t-6f0c14fee1900467d70202f7bf03f21d4af7ceeeac85990fc1dd6612cdd3e493</originalsourceid><addsrcrecordid>eNqNjsFKAzEURbNQsFb_IUs3gfeSTDKzrKXWQosuxnV5TV5oy3RmnMwI_r0F_QBXlwOHw70RM9AFKA9Q3In7nM8AzlWlmYnnjz7SyLJr5ftqrTbtyEPi4YrU9EeSSh8kZbmI5-mL2lHWRx6o_5anVu64oba70IO4TdRkfvzbuahfVvXyVW3f1pvlYqt6LHBULkFAm5ixArDORw8adPKHBCZpjJaSD8xMoSyqClLAGJ1DHWI0bCszF0-_2X7oPifO4_5yyoGb6wnuprxHrRFtYfC_qtG-ND_r9VOT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1221143278</pqid></control><display><type>article</type><title>Update on PEG-Interferon alpha -2b as Adjuvant Therapy in Melanoma</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Di Trolio, R ; Simeone, E ; Di Lorenzo, G ; Grimaldi, A M ; Romano, A ; Ayala, F ; Caraco, C ; Mozzillo, N ; Ascierto, P A</creator><creatorcontrib>Di Trolio, R ; Simeone, E ; Di Lorenzo, G ; Grimaldi, A M ; Romano, A ; Ayala, F ; Caraco, C ; Mozzillo, N ; Ascierto, P A</creatorcontrib><description>Based on the results of European Organization for Research and Treatment of Cancer (EORTC) 18991 trial, the US Food and Drug Administration (FDA) approved PEG-interferon alpha -2b (PEG-IFN)(Sylatron) as adjuvant therapy for high-risk melanoma. The EORTC 18991 trial was an open-label study of resectable stage III melanoma with 1,256 patients who were randomized to observation-alone or to treatment with PEG-IFN for up to 5 years. The median recurrence-free survival of the treatment groups was significantly longer, while overall survival, a secondary endpoint, was not significantly different between the two groups. This review, after a short summary of interferon alpha -2b trials, critically analyzes the EORTC18991 trial, as well as the subgroup results and future perspectives for this stage of disease.</description><identifier>ISSN: 0250-7005</identifier><language>eng</language><subject>Adjuvants ; Cancer ; Clinical trials ; Interferon ; Melanoma ; Reviews ; Risk groups ; Survival</subject><ispartof>Anticancer research, 2012-09, Vol.32 (9), p.3901-3909</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Di Trolio, R</creatorcontrib><creatorcontrib>Simeone, E</creatorcontrib><creatorcontrib>Di Lorenzo, G</creatorcontrib><creatorcontrib>Grimaldi, A M</creatorcontrib><creatorcontrib>Romano, A</creatorcontrib><creatorcontrib>Ayala, F</creatorcontrib><creatorcontrib>Caraco, C</creatorcontrib><creatorcontrib>Mozzillo, N</creatorcontrib><creatorcontrib>Ascierto, P A</creatorcontrib><title>Update on PEG-Interferon alpha -2b as Adjuvant Therapy in Melanoma</title><title>Anticancer research</title><description>Based on the results of European Organization for Research and Treatment of Cancer (EORTC) 18991 trial, the US Food and Drug Administration (FDA) approved PEG-interferon alpha -2b (PEG-IFN)(Sylatron) as adjuvant therapy for high-risk melanoma. The EORTC 18991 trial was an open-label study of resectable stage III melanoma with 1,256 patients who were randomized to observation-alone or to treatment with PEG-IFN for up to 5 years. The median recurrence-free survival of the treatment groups was significantly longer, while overall survival, a secondary endpoint, was not significantly different between the two groups. This review, after a short summary of interferon alpha -2b trials, critically analyzes the EORTC18991 trial, as well as the subgroup results and future perspectives for this stage of disease.</description><subject>Adjuvants</subject><subject>Cancer</subject><subject>Clinical trials</subject><subject>Interferon</subject><subject>Melanoma</subject><subject>Reviews</subject><subject>Risk groups</subject><subject>Survival</subject><issn>0250-7005</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqNjsFKAzEURbNQsFb_IUs3gfeSTDKzrKXWQosuxnV5TV5oy3RmnMwI_r0F_QBXlwOHw70RM9AFKA9Q3In7nM8AzlWlmYnnjz7SyLJr5ftqrTbtyEPi4YrU9EeSSh8kZbmI5-mL2lHWRx6o_5anVu64oba70IO4TdRkfvzbuahfVvXyVW3f1pvlYqt6LHBULkFAm5ixArDORw8adPKHBCZpjJaSD8xMoSyqClLAGJ1DHWI0bCszF0-_2X7oPifO4_5yyoGb6wnuprxHrRFtYfC_qtG-ND_r9VOT</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Di Trolio, R</creator><creator>Simeone, E</creator><creator>Di Lorenzo, G</creator><creator>Grimaldi, A M</creator><creator>Romano, A</creator><creator>Ayala, F</creator><creator>Caraco, C</creator><creator>Mozzillo, N</creator><creator>Ascierto, P A</creator><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20120901</creationdate><title>Update on PEG-Interferon alpha -2b as Adjuvant Therapy in Melanoma</title><author>Di Trolio, R ; Simeone, E ; Di Lorenzo, G ; Grimaldi, A M ; Romano, A ; Ayala, F ; Caraco, C ; Mozzillo, N ; Ascierto, P A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p151t-6f0c14fee1900467d70202f7bf03f21d4af7ceeeac85990fc1dd6612cdd3e493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adjuvants</topic><topic>Cancer</topic><topic>Clinical trials</topic><topic>Interferon</topic><topic>Melanoma</topic><topic>Reviews</topic><topic>Risk groups</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di Trolio, R</creatorcontrib><creatorcontrib>Simeone, E</creatorcontrib><creatorcontrib>Di Lorenzo, G</creatorcontrib><creatorcontrib>Grimaldi, A M</creatorcontrib><creatorcontrib>Romano, A</creatorcontrib><creatorcontrib>Ayala, F</creatorcontrib><creatorcontrib>Caraco, C</creatorcontrib><creatorcontrib>Mozzillo, N</creatorcontrib><creatorcontrib>Ascierto, P A</creatorcontrib><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Trolio, R</au><au>Simeone, E</au><au>Di Lorenzo, G</au><au>Grimaldi, A M</au><au>Romano, A</au><au>Ayala, F</au><au>Caraco, C</au><au>Mozzillo, N</au><au>Ascierto, P A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Update on PEG-Interferon alpha -2b as Adjuvant Therapy in Melanoma</atitle><jtitle>Anticancer research</jtitle><date>2012-09-01</date><risdate>2012</risdate><volume>32</volume><issue>9</issue><spage>3901</spage><epage>3909</epage><pages>3901-3909</pages><issn>0250-7005</issn><abstract>Based on the results of European Organization for Research and Treatment of Cancer (EORTC) 18991 trial, the US Food and Drug Administration (FDA) approved PEG-interferon alpha -2b (PEG-IFN)(Sylatron) as adjuvant therapy for high-risk melanoma. The EORTC 18991 trial was an open-label study of resectable stage III melanoma with 1,256 patients who were randomized to observation-alone or to treatment with PEG-IFN for up to 5 years. The median recurrence-free survival of the treatment groups was significantly longer, while overall survival, a secondary endpoint, was not significantly different between the two groups. This review, after a short summary of interferon alpha -2b trials, critically analyzes the EORTC18991 trial, as well as the subgroup results and future perspectives for this stage of disease.</abstract><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2012-09, Vol.32 (9), p.3901-3909 |
| issn | 0250-7005 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1221145319 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | Adjuvants Cancer Clinical trials Interferon Melanoma Reviews Risk groups Survival |
| title | Update on PEG-Interferon alpha -2b as Adjuvant Therapy in Melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T02%3A32%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Update%20on%20PEG-Interferon%20alpha%20-2b%20as%20Adjuvant%20Therapy%20in%20Melanoma&rft.jtitle=Anticancer%20research&rft.au=Di%20Trolio,%20R&rft.date=2012-09-01&rft.volume=32&rft.issue=9&rft.spage=3901&rft.epage=3909&rft.pages=3901-3909&rft.issn=0250-7005&rft_id=info:doi/&rft_dat=%3Cproquest%3E1221143278%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1221143278&rft_id=info:pmid/&rfr_iscdi=true |